Obesity Clinical Trial
Official title:
Influence of High-fat Overfeeding on Circulating Hepatokine Concentrations: a Randomised Crossover Study
The present study will investigate the effect of high-fat overfeeding on a group of
liver-secreted proteins linked to worsened blood sugar control, as well as proteins involved
in appetite control. Participants will consume both a high-fat diet, consisting of 50% extra
calories above their daily required intake, and a control diet, consisting of their normal
'habitual' diet, with each diet lasting seven days. The diets will be undertaken in a
randomised order, with a period of three weeks separating the two diets. Blood samples will
be taken before and after each diet to measure blood sugar control. Further blood samples
will also be taken 24 hours and 72 hours into each diet to see how levels of the liver and
appetite-regulating proteins change over the course of the seven days.
It is expected that blood sugar control will be worsened by the high-fat diet and this will
be accompanied by increases in levels of the liver-secreted proteins and an impaired release
of the appetite-regulating proteins into the blood.
In recent years, researchers have identified a number of liver-secreted proteins, termed
"hepatokines", which are thought to play an important role in inter-organ crosstalk between
the liver and other metabolically active tissues such as skeletal muscle and adipose tissue.
Specifically, previous studies have demonstrated that hepatokines contribute to whole body
glucose and lipid homeostasis through acting in an endocrine-like fashion. Understanding how
circulating concentrations of these hepatokines can be manipulated in humans is essential, as
impaired blood glucose and lipid control is a key feature of metabolic diseases, such as type
2 diabetes and non-alcoholic fatty liver disease.
Previous research at Loughborough University has found that acute high-fat overfeeding for up
to seven days can impair glycaemic control; however, the exact mechanisms responsible for
these detrimental changes are not fully understood. Based upon previous evidence that
hepatokine production is nutritionally modulated, the investigators believe that changes in
hepatokine production may play a role in the detrimental metabolic effects seen following
short-term, high-fat overfeeding which has implications for long-term metabolic health.
Appetite regulation is also thought to play a role in the pathophysiology of obesity and
insulin resistance, as the impaired secretion of several appetite regulatory hormones in both
fasting and postprandial conditions has been observed in obesity, which is characterised by
an chronic excessive energy intake. Therefore, the investigators are also interested to
examine the appetite regulatory hormone response to short-term, high-fat overfeeding.
The present study is a randomised, controlled, crossover study in which twelve recreationally
active, healthy males will consume both a hypercaloric, high-fat diet (consisting of 50%
extra energy above the daily requirement, 65% of which is fat) and a control diet (the
participants' habitual diet) in a randomised fashion. A three-week washout period will
separate the two diets in order to remove any lasting effects confounding the subsequent
diet.
Following a prescreening session in which anthropometric data will be collected, participants
will commence their first dietary condition. An oral glucose tolerance test will be performed
before and after the two diets to measure changes in glycaemic control/whole body insulin
sensitivity. Further blood samples will be taken 24 hours and 72 hours after commencing the
diets in order to observe the time course of any changes in circulating hepatokine and
appetite hormone concentrations. Physical activity will also be monitored for the duration of
the two dietary conditions to ensure that habitual physical activity levels are maintained.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |